Adakveo®
Adakveo® (crizanlizumab-tmca) is a prescription medicine used in people 16 years of age and older who have sickle cell disease to help reduce frequency of painful episodes Adakveo helps prevent pain crises (called vaso-occlusive crises, or VOCs) in patients with sickle cell disease (SCD). Vaso-occlusive crises occur when microcirculation is obstructed by “sickled” red blood cells. Adakveo works by binding to P-selectin, a protein that plays a central role in cellular interactions that can lead to vaso-occlusion. In its initial study, Adakveo was shown to reduce VOCs by about 45%.
For more information, visit the patient website for this drug. *Some browsers may reroute this link to the Prescribing Information.
Speak with your healthcare provider to learn if this drug is right for you.
MANUFACTURER: Novartis Pharmaceuticals Corporation |
CLASS: Miscellaneous/Unclassified agents |
WHAT IT TREATS: |
PRESCRIBED BY: Hematologists |
HOW ADMINISTERED: IV Infusion |
FREQUENCY: Administered every four weeks after two starter doses. |
Length of infusion: About 30 minutes |